Welcome to our dedicated page for Enzon Pharma news (Ticker: ENZN), a resource for investors and traders seeking the latest updates and insights on Enzon Pharma stock.
Enzon Pharmaceuticals, Inc. (ENZN) generates news primarily through its role as a public company acquisition vehicle and its involvement in merger activity. Recent coverage focuses on its definitive Agreement and Plan of Merger with Viskase Companies, Inc., under which Viskase will merge with and into a wholly owned subsidiary of Enzon in an all-stock transaction. Company announcements describe that, following the merger, the combined company is expected to operate under the name "Viskase Holdings, Inc." and trade on an OTC market tier.
News about ENZN highlights key transaction terms, including the exchange ratios between Enzon common stock, Enzon’s Series C Non-Convertible Redeemable Preferred Stock, and Viskase common stock. Updates have covered changes to these ratios, the anticipated post-merger ownership split in which current Viskase stockholders are expected to own 55% of the combined company, and the requirement for Enzon to effect a 1-for-100 reverse stock split of its common stock prior to the merger’s effective time.
Additional news items relate to amendments to Enzon’s Section 382 Rights Agreement, as disclosed in Form 8-K filings. These stories describe repeated adjustments to the Final Expiration Date of the rights issued under the agreement and management’s view that the revised dates are in the best interests of the company and its stockholders. Coverage also notes Enzon’s statements that the merger structure is intended to preserve its net operating losses and other tax benefits for potential use by the combined company.
Investors following ENZN news can expect updates on the progress of the Viskase merger, changes to transaction terms, regulatory filing milestones such as the planned Form S-4 registration statement, and further amendments to rights agreements or support agreements involving major stockholders.
Enzon (OTCQB: ENZN) announced completion of its exchange offer to convert Series C Non-Convertible Redeemable Preferred Stock into common stock. The offer expired March 24, 2026 at 5:00 p.m. ET. 339 shares were validly tendered and accepted, representing less than 1% of 40,000 outstanding Series C shares. The offer was made via a prospectus/consent solicitation filed January 28, 2026 and declared effective January 30, 2026. Continental Stock Transfer & Trust Company served as depositary.
Enzon (OTCQB: ENZN) announced the previously approved 1-for-100 reverse stock split effective March 24, 2026 at 4:30 pm ET. Post-split shares are expected to trade on the OTCQB on March 25, 2026 under temporary symbol ENZND for 20 trading days.
No fractional shares will be issued; fractional entitlements will receive a cash payment. The reverse split was completed to free authorized shares for the anticipated merger with Viskase Companies and to support share issuances under the Company’s exchange offer for Series C preferred stock.
Enzon (OTCQB: ENZN) extended its exchange offer for Series C Non-Convertible Redeemable Preferred Stock to 5:00 p.m. ET on March 24, 2026. As of 5:00 p.m. ET on March 18, 2026, 339 shares were validly tendered, under 1% of 40,000 outstanding Series C shares. The exchange ratio uses each share's liquidation preference divided by $7.83 after the Reverse Stock Split. Deposit and exchange agents and an information agent remain appointed; previously tendered shares need no re-tendering.
Enzon (OTCQB: ENZN) extended its exchange offer for Series C Non-Convertible Redeemable Preferred Stock. The offer now expires at 5:00 p.m. ET on March 19, 2026, unless further extended. As of March 13, 2026, 342 shares were validly tendered, under 1% of 40,000 outstanding.
Each Series C share may be exchanged for Common Stock equal to the share's liquidation preference divided by $7.83 (post‑reverse split). Deposit and exchange agents and an information agent are appointed for tender procedures.
Enzon (OTCQB: ENZN) extended its exchange offer for Series C Non-Convertible Redeemable Preferred Stock to 5:00 p.m. ET on March 16, 2026. The offer lets holders exchange Series C preferred shares for Enzon common stock based on each share's liquidation preference divided by $7.83 after a reverse stock split.
As of 5:00 p.m. ET on March 10, 2026, 340 shares had been validly tendered and not withdrawn, representing less than 1% of the 40,000 Series C shares outstanding.
Enzon (OTCQB: ENZN) extended its exchange offer for Series C non-convertible redeemable preferred stock to one minute after 11:59 p.m. ET on March 11, 2026. As of 5:00 p.m. ET on March 6, 2026, 339 shares were validly tendered, representing <1% of 40,000 outstanding shares. The exchange rate uses each share's liquidation preference divided by $7.83 after the reverse stock split. All other offer terms remain unchanged; holders who already tendered need not re-tender.
Enzon (OTCQB: ENZN) extended its exchange offer for Series C Non-Convertible Redeemable Preferred Stock to expire one minute after 11:59 p.m. ET on March 9, 2026, unless further extended. As of 5:00 p.m. ET on Feb. 26, 2026, 12 shares had been validly tendered, representing <0.001% of the 40,000 Series C shares outstanding.
The offer lets holders exchange each Series C share for Common Stock based on the share’s liquidation preference divided by $7.83 (post-reverse split). Terms remain as set in the January 28–30, 2026 filings.
Enzon (OTCQB: ENZN) commenced an exchange offer allowing holders of its Series C Non-Convertible Redeemable Preferred Stock to exchange outstanding preferred shares for Enzon common stock. Each Series C share exchanges for common stock equal to its liquidation preference divided by $7.83 after a reverse stock split. The offer expires 1 minute after 11:59 p.m. ET on February 27, 2026. There are 40,000 Series C shares outstanding as of January 30, 2026. HKL & Co. is Information Agent; Continental Stock Transfer & Trust is Exchange Agent.
Enzon (OTCQB: ENZN) and Viskase (OTC Pink: VKSC) amended their merger agreement on Oct 24, 2025. Under the Amendment, Viskase stockholders will own 55% and Enzon stockholders 45% of the combined company.
Key changes include using the 20-day VWAP to convert Series C preferred into Enzon common, a 1-for-100 reverse stock split of Enzon common before closing, a reduction in Enzon's required closing cash, and an extension of the termination deadline to Mar 31, 2026. Icahn Enterprises Holdings amended its support agreement to deliver consents and exchange its Series C preferred prior to closing. Enzon expects combined company NOLs to be preserved.